102 articles tagged with #drug-discovery. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
Tim Cernak, a chemist who spent nearly two decades developing precision cancer and disease therapies at Merck, is transitioning his expertise toward applying pharmaceutical chemistry principles to nature-inspired drug design. This shift reflects a broader professional trend where traditional pharma scientists are redirecting their skills toward sustainable, nature-based solutions in medicine.
FreeBridge, a new computational method based on Schrödinger Bridges, addresses a fundamental challenge in cellular biology by inferring continuous cell transition pathways from static snapshots. The approach constrains predicted intermediate cell states to geometrically valid regions observed in real data, improving both accuracy and biological interpretability in perturbation modeling across multiple imaging datasets.
Researchers introduce MolGram, a neural architecture that enhances transformer-based language models for molecular SMILES strings by integrating a conditional n-gram memory module. This approach addresses the locality gap in character-level tokenization, enabling models to better capture chemical motifs while improving performance across molecule generation, reaction prediction, and retrosynthesis tasks with significantly fewer parameters than baseline models.
Researchers introduce ReAlignFit, a machine learning framework that enhances molecular relational learning by incorporating chemical knowledge through induced fit principles to improve prediction stability across different molecular datasets. The method addresses limitations in attention-based alignment mechanisms by using bias correction functions and information bottleneck optimization to better predict molecular binding compatibility.
Researchers demonstrate that augmenting graph neural networks with pharmacogenomic data from the PharmGKB database significantly improves drug-drug interaction predictions, particularly for CYP-mediated interactions. While knowledge graph augmentation shows substantial gains in DDI classification tasks, the approach reveals fundamental limitations in generalization to unseen drugs, suggesting that molecular structure alone constrains model performance.
Researchers have developed EssentialGIN, a graph isomorphism neural network approach for predicting essential genes by embedding proteins within protein-protein interaction networks while integrating biological data like gene expression and subcellular localization. The method significantly outperforms traditional centrality measures and other machine learning approaches, particularly for complex organisms like humans.
Researchers demonstrate that large language models can design molecules with chemist-level precision by replacing simple numerical feedback with detailed physicochemical analysis. The approach couples retrieval-augmented generation with self-reflection modules that feed orbital energies and atomic charges back into design iterations, achieving near-perfect accuracy on HOMO-LUMO gap targets and 100% success rates on moderate molecular design tasks.
Researchers propose AMREC, a new agentic framework that improves text-guided molecular generation by shifting focus from merely fixing invalid chemical structures to preserving target-relevant molecular identity. The approach outperforms existing correction strategies by combining molecule-aware tracking with expanded candidate exploration, achieving superior recovery across multiple evaluation metrics on invalid molecular drafts.
Researchers introduce MuCO, a generative AI method for modeling cyclic peptide structures through multi-stage conformation optimization. The approach outperforms existing methods in stability, diversity, and efficiency, offering significant implications for computational drug discovery and peptide-based therapeutic development.
OpenAI has enhanced GPT-Rosalind with advanced capabilities for biological reasoning, medicinal chemistry, genomics analysis, and experimental workflows. These improvements position the model as a specialized tool for accelerating life sciences research and drug discovery processes.
Researchers introduce ATOM, a multi-agent framework that treats molecular optimization as tree-structured search where specialized agents coordinate across different pathways rather than enforcing consensus. The method demonstrates improved performance on multi-objective molecular design benchmarks by maintaining diverse trade-offs and exploring multiple promising trajectories simultaneously.
Researchers introduce SGAP-PPIS, a graph neural network model that uses adaptive propagation guided by protein structure geometry to predict protein-protein interaction sites more accurately. The model dynamically adjusts how information flows between residues based on their local geometric environment, outperforming fixed propagation approaches in distinguishing true interaction sites from similar non-interacting regions.
Researchers introduce GeoCoupling, a framework that optimizes how different molecular modalities (protein sequences and structures) are temporally coupled during AI model training and generation. The approach outperforms existing synchronous coupling methods in biomolecular co-design tasks, producing molecules with improved physical validity and diversity for drug design and protein engineering applications.
Researchers have developed a method to enhance generative AI models that simulate protein dynamics by introducing a history-dependent bias that steers sampling toward undiscovered molecular states. The technique achieves 37× faster coverage of low-energy protein configurations compared to standard approaches, significantly improving the practical utility of AI-accelerated molecular simulation.
Researchers propose a new benchmarking framework for evaluating large language models in retrosynthesis planning, introducing ChemCensor—a metric prioritizing chemical plausibility over exact-match accuracy—and CREED, a dataset of millions of validated reaction records that improves model performance beyond existing LLM baselines.
Researchers introduce ProtLiD², a discrete diffusion model that co-designs protein sequences and structures while conditioning on ligand information, achieving significant improvements in fold confidence and ligand-binding accuracy compared to existing methods. The model demonstrates practical advantages in both whole-protein and active-site pocket design tasks.
A new framework argues that AI in biomedicine is transitioning from predictive systems based on historical data to interventional intelligence that can model biological responses to novel therapies. The shift reflects a fundamental architectural limitation: traditional AI cannot reason about unseen interventions, making disease-level models that simulate outcomes under perturbation essential for clinical decision-making.
Biohub has launched an AI toolkit that democratizes drug discovery by enabling smaller biotech firms to access advanced protein design and AI-powered research capabilities previously available only to large pharmaceutical companies. This development has the potential to reshape the biotech industry by lowering barriers to entry and accelerating innovation across the sector.
Sanofi is developing proprietary AI tools and workflows instead of purchasing off-the-shelf agentic AI products from SaaS vendors, positioning itself to gain competitive advantages in pharmaceutical development. This strategic shift reflects growing pharmaceutical interest in building custom AI capabilities tailored to specific industry needs rather than relying on generic enterprise solutions.
Researchers introduce PolyFusionAgent, a multimodal AI framework combining a foundation model (PolyFusion) with an autonomous design agent (PolyAgent) for polymer discovery. The system integrates multiple polymer representations into a shared latent space to predict properties and generate novel structures, while grounding predictions in scientific literature for actionable design decisions.
Researchers introduce SCENE, a multi-agent AI framework that transforms general biomedical knowledge into specific, evidence-supported hypotheses grounded in experimental data. The system successfully identifies patient subgroups with different treatment responses in clinical trials and context-specific biological responses in genomic studies, bridging the gap between broad theoretical knowledge and actionable dataset-specific insights.
Researchers introduce Periodic-TDL, a deep learning framework using topological data analysis to predict polymer properties more accurately than existing models. The approach captures many-body interactions across polymer chains and has been validated against experimental data from newly synthesized polymers, demonstrating practical utility in accelerating polymer discovery.
Researchers introduce TriProRep, a protein representation learning method that jointly models amino acid identity, backbone geometry, and full-atom geometry to improve protein structure prediction. The new approach outperforms sequence-only and prior structure-aware models across multiple benchmarks including homodimer co-folding and monomer structure prediction tasks.
Connor Coley is advancing machine learning applications in chemistry to accelerate drug discovery and compound design. This work represents a convergence of AI with pharmaceutical research, enabling computational models to understand and predict chemical behavior more effectively than traditional methods.
Calico Life Sciences has implemented Co-Scientist, an AI tool designed to aggregate dispersed research findings and identify new research directions in aging studies. This application demonstrates how AI systems can accelerate scientific discovery by synthesizing complex datasets across multiple studies.
